A groundbreaking long-acting reversible contraceptive (LARC) has entered late-stage clinical trials, offering a potential new option for individuals seeking highly effective birth control with minimal maintenance. The new device, a subdermal implant smaller than a matchstick, releases a novel progestin hormone that prevents ovulation for up to five years. Early results indicate a 99.8% efficacy rate, surpassing many existing LARCs like IUDs and Nexplanon.
Researchers highlight that this implant has fewer hormonal side effects, such as weight gain and mood swings, which have been common complaints with current options. The trial, conducted across 30 sites in the U.S., Europe, and Africa, included over 2,000 participants, with 98% reporting satisfaction after one year. If approved by the FDA, this implant could be available by late 2025.
Public health experts emphasize that expanding LARC options is crucial for reducing unintended pregnancies, particularly in regions with limited healthcare access. However, some advocates caution that cost and insurance coverage will determine its real-world impact. Unlike older LARCs, which can be expensive without insurance, manufacturers claim this new implant will be competitively priced.
You Might Be Interested In:
- What is Nausea and Vomiting During Pregnancy?
- Have You Noticed a Loss of Appetite or Sudden Food Aversions?
- What is Sudden Sharp Pains in the Lower Abdomen During Pregnancy?
